OncoMatch/Clinical Trials/NCT07108270
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Is NCT07108270 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dostarlimab and Carboplatin for neoplasms, endometrial.
Treatment: Dostarlimab · Carboplatin · Paclitaxel — The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or anti-CTLA-4 therapy
prior therapy with an anti- Programmed death protein 1 (PD-1), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent
Cannot have received: anticancer therapy
received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days prior to the first dose of study intervention
Lab requirements
Blood counts
adequate organ function, as assessed by hematologic parameters
Kidney function
adequate organ function, as assessed by renal parameters
Liver function
adequate organ function, as assessed by hepatic parameters
adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify